Navigation Links
Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
Date:11/3/2011

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication in the Journal of Hematology & Oncology of:  Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant severe chronic idiopathic neutropenia following treatment with Telintra; Roger M. Lyons, MD et al. from the Cancer Care Centers of South Texas; Journal of Hematology & Oncology 2011, 4:43; doi:10.1186/1756-8722-4-43, November 2, 2011.  This publication highlights an important observation that Telintra produced a striking and sustained hematologic response in white blood cell levels in an ICN patient who had an inadequate response to the standard of care, granulocyte colony stimulating factors (G-CSF).  The publication may be found at http://www.jhoonline.org/content/4/1/43/abstract.  

This case report describes a patient with severe ICN who experienced frequent episodes of sepsis requiring hospitalizations and prolonged courses of antibiotics for the preceding four years.  She was treated with G-CSF and had delayed, variable, and transient responses. After receiving Telintra therapy, her white blood cell levels stabilized, temperature normalized, and chronic infections resolved. The response to Telintra treatment has been sustained for over eight months at the time of this report and continues. These results may suggest a potential role for Telintra tablets in the treatment of patients who are not responsive to G-CSF injections.   Telintra, a GST P1-1 inhibitor, may achieve this effect by activating Jun kinase (JNK), promoting the growth and maturation of blood progenitor stem cells.    

Background on Severe Idiopathic Chronic Neutropenia

Severe Chronic Idiopathic Neutropenia is a rare hematologic disorder characterized by persistent severe low white blood cell levels, leading to recurrent fevers, chronic mouth inflammation and life-threatening infections. The severity and risk of complications, including serious infections, are inversely proportional to the low white blood cell levels, with the greatest problems occurring in patients with levels of less than 500.  G-CSF has been the standard therapy for increasing white blood cell levels in these patients. A subgroup of patients does not respond to subcutaneous administration of G-CSF and patients receiving chronic G-CSF therapy may experience side effects of bone and muscle pain as well as low platelet level and enlarged spleen, complicating their therapy.

Background on Telintra

Telintra is an investigational agent in development for the treatment of a variety of neoplastic and non-neoplastic hematologic disorders, including myelodysplastic syndrome (MDS), and has demonstrated significant improvement in the induction of growth and differentiation of hematologic precursor stem cells as well as an increase in apoptosis of malignant cells.  Telintra is an inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1), a negative regulator of JNK.  Treatment of human cells with Telintra leads to the activation of JNK, which promotes the growth and differentiation of hematopoietic stem cell precursors.  Telintra treatment has shown significant improvement in neutrophil levels in several clinical trials in MDS.  More information about Telintra may be found at www.telik.com.  

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating ICN and MDS, whether Telintra treatment results in hematologic improvement in patients with ICN and MDS, and the capability of Telintra to induce apoptosis in malignant cells and treat hematologic disorders in general.  These forward-looking statements are based upon Telik's current expectations and there are important factors that could cause actual results to differ materially from those indicated by these forward-looking statements.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ending June 30, 2011.  Telik does not undertake any obligation to update forward looking statements contained in this press release.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
3. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
4. Telik Announces First Quarter 2011 Financial Results
5. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
6. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
7. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
8. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
9. Telik Announces Presentation at American Society of Hematology Annual Meeting
10. Telik Announces Third Quarter 2010 Financial Results
11. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):